|
Agentix Corp
FWDR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Agentix 's sales fell
in II. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.29 %
Agentix net loss decreased from $0 millions, to $0 millions in II. Quarter 2024,
• More on FWDR's Growth
|
|
Agentix realized a net loss in trailing twelve months.
Agentix realized cash reduction of $ -0 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.47.
• More on FWDR's Valuation
|
|
|
|
|
Agentix realized net loss in trailing twelve months.
Agentix realized cash outflow of $ -0per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.47.
• More on FWDR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com